People with mild-to-moderate Alzheimer’s disease treated for three weeks with sargramostim, a medication that activates the immune system, showed improvements in cognition in a small clinical trial. These results support further investigation of sargramostim — and, more generally, the strategy of targeted immune activation — in treating Alzheimer’s, its researchers said. Findings were published in Alzheimer’s & Dementia: Translational Research and Clinical Interventions, in the study, “Safety and efficacy of sargramostim (GM‐CSF) in the treatment of…
You must be logged in to read/download the full post.
The post Sargramostim, Immune System Activator, May Aid Cognition, Small Trial Finds appeared first on BioNewsFeeds.